The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Seasonal increases in peripheral innate lymphoid type 2 cells are inhibited by subcutaneous grass pollen immunotherapy
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Allergen challenge in AR subjects induces an increased number of peripheral serum ILC2s332,333; however, a similar increase in the nasal mucosa is yet to be demonstrated.”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [333]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*
Bousquet, J., Khaltaev, N., Cruz, A. A., Denburg, J., Fokkens, W. J., Togias, A., Zuberbier, T., Baena‐Cagnani, C. E., Canonica, G. W., Van Weel, C., et al. (2008) · Allergy · doi:10.1111/j.1398-9995.2007.01620.x · Cited by 4,729
Self-citationInnate lymphoid cells — a proposal for uniform nomenclature
Spits, H., Artis, D., Colonna, M., Diefenbach, A., Disanto, J. D., Eberl, G., Koyasu, S., Locksley, R., McKenzie, A., Mebius, R., et al. (2013) · Nature reviews. Immunology · doi:10.1038/nri3365 · Cited by 2,380
Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity
Neill, D. R., Wong, S. H., Bellosi, A., Flynn, R. J., Daly, M. G., Langford, T. K. A., Bucks, C. M., Kane, C. M., Fallon, P. G., Pannell, R., et al. (2010) · Nature · doi:10.1038/nature08900 · Cited by 2,079
A role for IL-25 and IL-33–driven type-2 innate lymphoid cells in atopic dermatitis
Salimi, M., Barlow, J. L., Saunders, S. P., Xue, L., Gutowska‐Owsiak, D., Wang, X., Huang, L.-C., Johnson, D., Scanlon, S. T., McKenzie, A. N. J., et al. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20130351 · Cited by 1,012
Type 2 Innate Lymphoid Cells Drive CD4+ Th2 Cell Responses
Mirchandani, A. S., Besnard, A., Yip, E., Scott, C. L., Bain, C. C., Cerovic, V., Salmond, R. J., & Liew, F. Y. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1300974 · Cited by 302
Shaw, J. L., Fakhri, S., Citardi, M. J., Porter, P. C., Corry, D. B., Kheradmand, F., Liu, Y., & Luong, A. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201212-2227oc · Cited by 278
Mechanisms of immunotherapy to aeroallergens
Shamji, M. H., & Durham, S. R. (2011) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2011.03804.x · Cited by 157
Self-citationProstaglandin D2 regulates human type 2 innate lymphoid cell chemotaxis
Chang, J. E., Doherty, T. A., Baum, R. E., & Broide, D. H. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.09.020 · Cited by 126
Doherty, T. A., Scott, D., Walford, H. H., Khorram, N., Lund, S., Baum, R., Chang, J., Rosenthal, P., Beppu, A., Miller, M., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.12.1086 · Cited by 119
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 201
Wirtz, S. J., Schulz-Kuhnt, A., Neurath, M. F., & Atreya, I. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.688879 · Cited by 19
“Consistent with their role as drivers of asthma symptoms, ILC2s were increased during the allergy season (92) and their local numbers in the lung increased significantly after segmented allergen challenge and went along with an increased expression of genes related to type 2 immunity (93).”
BackgroundGroup 2 innate lymphoid cells and eosinophilic chronic rhinosinusitis
Tojima, I., & Shimizu, T. (2018) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000496 · Cited by 18
Liu, W., Zeng, Q., Wen, Y., Tang, Y., Yan, S., Li, Y., Zhou, L., & Luo, R. (2020) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2020.08.005 · Cited by 18
Schwab, A. D., & Poole, J. A. (2023) · Current Allergy and Asthma Reports · doi:10.1007/s11882-023-01079-w · Cited by 17
TNF Superfamily and ILC2 Activation in Asthma
Matsuyama, T., Salter, B., Fard, N. E., Machida, K., & Sehmi, R. (2024) · Biomolecules · doi:10.3390/biom14030294 · Cited by 16
Biomarkers for antigen immunotherapy in allergy and type 1 diabetes
Odegard, J., Nepom, G. T., & Wambre, E. R. (2015) · Clinical Immunology · doi:10.1016/j.clim.2015.05.023 · Cited by 15
“Innate lymphoid type 2 cells (ILC2), for example, have been recently reported to decrease dramatically after successful grass pollen subcutaneous immunotherapy in patients with seasonal allergic rhinitis [14].”
BackgroundThe effects of resiquimod in an ovalbumin-induced allergic rhinitis model
Qu, S., Qin, T., Li, M., Zhang, S., Ye, L., Wei, J., Fan, H., & Chen, B. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.04.015 · Cited by 15
Cavagnero, K. J., & Doherty, T. A. (2020) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2020.09.011 · Cited by 14
Immune checkpoint molecules in prevention and development of asthma
Kanannejad, Z., Soleimanian, S., Ghahramani, Z., Sepahi, N., Mohkam, M., Alyasin, S. S., & Kheshtchin, N. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1070779 · Cited by 14
Ohashi‐Doi, K., Lund, K., Mitobe, Y., & Okamiya, K. (2019) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b19-00093 · Cited by 14
The role of ICOS in allergic disease: Positive or Negative?
Zhang, X., Hu, X., Tian, T., & Pang, W. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108394 · Cited by 14
L-Phenylalanine is a metabolic checkpoint of human Th2 cells
Kulkarni, A. J., Rodríguez‐Coira, J., Stocker, N., Radzikowska, U., García-Cívico, A. J., Dolset, M. I. D., Contreras, N., Parages, I. J., Sanchez, V. S., Serrano, P., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102466 · Cited by 12
The Inhibition of Group II Innate Lymphoid Cell Response by IL‐27 in Allergic Rhinitis
Luo, X., Zeng, Q., Li, Y., Tang, Y., Liu, W., & Luo, R. (2020) · Journal of Immunology Research · doi:10.1155/2020/6661524 · Cited by 14
“Studies have found that the frequency of ILC2 in the peripheral blood of AR patients sensitized to pollen increased in pollen season [13].”
Human Immune Monitoring Techniques during Food Allergen Immunotherapy
Rust, B. J., & Wambre, E. R. (2017) · Current Allergy and Asthma Reports · doi:10.1007/s11882-017-0689-y · Cited by 13
LNIT-Local nasal immunotherapy in allergic rhinitis: revisited evidence and perspectives
Kanjanawasee, D., & Tantilipikorn, P. (2022) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000830 · Cited by 12
Allergen Immunotherapy in children with respiratory allergic diseases
Arasi, S., Pajno, G. B., Panasiti, I., Sandoval, M., & Lozano, M. A. (2020) · Minerva Pediatrics · doi:10.23736/s0026-4946.20.05959-9 · Cited by 12
NLRP3 priming due to skin damage precedes LTP allergic sensitization in a mouse model
Pazos‐Castro, D., Klein, Z. G., Yuste‐Montalvo, A., Hernández‐Ramírez, G., Romero‐Sahagun, A., Esteban, V., Garrido‐Arandia, M., Tomé‐Amat, J., & Díaz‐Perales, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-07421-y · Cited by 12
He, Y., Zhou, Y., Shao, Q., Gan, C., Chen, M., Bao, Y.-L., Gu, H., Zhang, S., Cui, Y., & Tian, M. (2019) · Journal of Immunology Research · doi:10.1155/2019/7024905 · Cited by 12
“Research confirmed that SCIT to patients with seasonal allergic rhinitis can reduce ILC2 percentage in the peripheral blood, comparing to patients who did not receive subcutaneous desensitization [6].”
BackgroundPersonalized therapies for the treatment of allergic rhinitis
Licari, A., Castagnoli, R., Tosca, M. A., Marseglia, G. L., & Ciprandi, G. (2019) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2019.1681896 · Cited by 12
Tong, Y., Wang, L., Wang, L., Song, J., Fan, J., Lai, C., Bao, J., Weng, C., Wang, Y., Shuai, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1264071 · Cited by 11
Novel Approaches to Allergen Immunotherapy for Respiratory Allergies
Lao‐Araya, M. (2024) · Pharmaceuticals · doi:10.3390/ph17111510 · Cited by 11
Self-citationTherapeutic vaccines for allergic disease
Gutowska‐Owsiak, D., & Ogg, G. S. (2017) · npj Vaccines · doi:10.1038/s41541-017-0014-8 · Cited by 11
Inflammatory cytokines and risk of allergic rhinitis: A Mendelian randomization study
Zhang, X., Wang, P., Dang, Q., Huang, X., Xiao, Y., & Guan, B. (2024) · Cytokine · doi:10.1016/j.cyto.2024.156547 · Cited by 11
Vaccines and adjuvants in allergen specific immunotherapy: current status and future directions
Zheng, Y., & Subiza, J. L. (2025) · Allergy medicine. · doi:10.1016/j.allmed.2025.100065 · Cited by 10
de Sousa, T. R., Sgnotto, F. D. R., Fagundes, B. O., Duarte, A. J. D. S., & Victor, J. R. (2021) · Frontiers in Allergy · doi:10.3389/falgy.2021.650235 · Cited by 10
“Lastly, it was also demonstrated that ILC2 cells increase during the grass pollen season and are inhibited by subcutaneous immunotherapy (60), suggesting some importance to ILC2 cell maturation in the therapeutic context.”
BackgroundTenn, M. W., Thiele, J., Steacy, L. M., Adams, D. E., & Ellis, A. K. (2018) · Allergy · doi:10.1111/all.13614 · Cited by 10
“These findings suggest that in pollen‐sensitized asymptomatic individuals, the change in peripheral ILC2s after a high‐dose pollen challenge may better reflect symptom severity compared to post‐challenge measurements alone, as observed in symptomatic individuals during pollen season.(5) To investigate local ILC2 respo…”
ResultWang, W., & Yin, J. (2019) · Scandinavian Journal of Immunology · doi:10.1111/sji.12817 · Cited by 10
Falquet, M., Ercolano, G., Jandus, P., Jandus, C., & Trabanelli, S. (2021) · Journal of Asthma and Allergy · doi:10.2147/jaa.s304126 · Cited by 11
“patients responding to allergen-specific immunotherapy (AIT), but not in non-responders.(53) To evaluate whether”
BackgroundMagnan, A., Nicolas, J., Caimmi, D. P., Vocanson, M., Haddad, T., Colas, L., Scurati, S., Mascarell, L., & Shamji, M. H. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13020324 · Cited by 10
“During AIT, both ILC2s and ILC10s are rebalanced.”
BackgroundInfluentialSelf-citationGotoh, M., & Kaminuma, O. (2021) · Pathogens · doi:10.3390/pathogens10020147 · Cited by 9
Allergen immunotherapy: progress and future outlook
Šošić, L., Paolucci, M., Flory, S., Jebbawi, F., Kündig, T. M., & Johansen, P. (2023) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2023.2209319 · Cited by 9
“With the course of AIT, a decrease in the production of TH2 cytokines (e.g. IL-4, IL-5, and IL-13) and an upregulation of TH1 (e.g. IFN-γ) and regulatory cytokines (e.g. IL-10 and TGF-β) is expected [131].”
BackgroundInfluentialPlasticity and regulatory mechanisms of human ILC2 functions
Maggi, L., Capone, M., Mazzoni, A., Liotta, F., Cosmi, L., & Annunziato, F. (2020) · Immunology Letters · doi:10.1016/j.imlet.2020.08.004 · Cited by 9
Dogmas, challenges, and promises in phase III allergen immunotherapy studies
de Kam, P., Kramer, M. F., Shamji, M. H., Oluwayi, K., Heath, M. D., Jensen‐Jarolim, E., Berger, M., Berger, U. E., Graessel, A., Sellwood, F., et al. (2021) · World Allergy Organization Journal · doi:10.1016/j.waojou.2021.100578 · Cited by 10
Self-citationTojima, I., Murao, T., Kawakita, K., Nakamura, K., Arai, H., Matsumoto, K., Shimizu, S., Kouzaki, H., & Shimizu, T. (2022) · Auris Nasus Larynx · doi:10.1016/j.anl.2022.11.006 · Cited by 8
Immunology of allergen immunotherapy
Rahman, R., & Wesemann, D. R. (2022) · Immunotherapy Advances · doi:10.1093/immadv/ltac022 · Cited by 8
Allergen-Specific Immunotherapy
Steveling, E. H. (2016) · European Medical Journal · doi:10.33590/emj/10314632 · Cited by 8
Self-citationPotential Effects of AIT on Nonspecific Allergic Immune Responses or Symptoms
Nakagome, K., Fujio, K., & Nagata, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113776 · Cited by 7
Pavlova, K. S., Kurbacheva, O. M., Galitskaya, M. A., & Smirnov, D. S. (2017) · Russian Journal of Allergy · doi:10.36691/rja290 · Cited by 7
Evolution of Immunotherapy Against Pollen Allergy
Gianni, M. (2023) · Current Protein and Peptide Science · doi:10.2174/1389203724666230303091754 · Cited by 7
Liu, Y., Yao, Y., Wang, Z.-Z., Ning, Q., & Liu, Z. (2018) · Clinical & Experimental Allergy · doi:10.1111/cea.13128 · Cited by 7
“On the contrary, the frequency of peripheral ILCs decreases in AR patients after subcutaneous immunotherapy, which is possibly due to the suppression mediated by IL-10 Tregs.(54) Tregs suppress the function of ILC2s through IL-10 and TGF-b production and/or inducible T cell costimulator (ICOS)-ICOS ligand interaction,…”
BackgroundInnate Lymphoid Cells in Airway Inflammation
Pasha, M. A., & Yang, Q. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-63046-1_11 · Cited by 7
Anti-inflammatory roles of interleukin-35 in the pathogenesis of Japanese cedar pollinosis
Kouzaki, H., Arai, Y., Nakamura, K., Murao, T., Tojima, I., Shimizu, S., Yuta, A., & Shimizu, T. (2021) · Asia Pacific Allergy · doi:10.5415/apallergy.2021.11.e34 · Cited by 7
“Th2 cells and ILC2s produce type 2 cytokines and are important inflammatory cells in the pathogenesis of AR [16], and B cells also play crucial roles by producing antigen-specific IgE.”
BackgroundGrass Pollen Immunotherapy: Where are We Now
Würtzen, P. A., Gupta, S., Brand, S., & Andersen, P. S. (2016) · Immunotherapy · doi:10.2217/imt.16.1 · Cited by 7
c-Rel Is Required for IL-33-Dependent Activation of ILC2s
Zaini, A., Fulford, T. S., Grumont, R. J., Runting, J., Rodrigues, G., Ng, J., Gerondakis, S., Zaph, C., & Scheer, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.667922 · Cited by 6
Roles of Clara cell 10-kD protein and type 2 innate lymphoid cells in allergic rhinitis
Long, X., Wang, N., & Zhang, X. (2021) · Cell Cycle · doi:10.1080/15384101.2021.1966961 · Cited by 6
“Increased levels of ILC2s were found in AR patients’ peripheral blood [15].”
BackgroundEffects of subcutaneous immunotherapy in allergic rhinitis children sensitive to dust mites
Lin, Y., Liu, J., He, J., Wu, L., Li, S., Cheng, B., Shao, Y., Zhang, Y., Wang, Y., Tang, L., et al. (2023) · Allergologia et Immunopathologia · doi:10.15586/aei.v51i1.666 · Cited by 6
Allergen immunotherapy for respiratory allergies in clinical practice: A comprehensive review
Lao‐Araya, M., Sompornrattanaphan, M., Kanjanawasee, D., & Tantilipikorn, P. (2022) · Asian Pacific Journal of Allergy and Immunology · doi:10.12932/ap-260722-1418 · Cited by 6
“18-20 18-20 Although, skewing of innate and adaptive immune response to a regulatory phenotype is a key event of successful clinical improvement by AIT, the immunological markers which can be consistently correlated with clinical improvements or predictive of long-term tolerance remain elusive.”
Self-citationPathological and therapeutic roles of innate lymphoid cells in diverse diseases
Kim, J., Kim, G., & Min, H. (2017) · Archives of Pharmacal Research · doi:10.1007/s12272-017-0974-2 · Cited by 6
“In addition, an increase in the number of peripheral-blood ILC2s is observed in patients with AR during pollen season, indicating the contribution of ILC2s to inflammatory responses in AR (Lao-Araya et al. 2014).”
BackgroundRole of Allergen Immunotherapy in Asthma Treatment and Asthma Development
Nakagome, K., & Nagata, M. (2020) · Allergies · doi:10.3390/allergies1010003 · Cited by 5
“As for type-2 innate lymphoid cells (ILC2), which are also important sources of Th2 cytokines such as IL-5 and IL-13, allergen immunotherapy decreases the number of ILC2 in peripheral blood [42], although this finding is controversial [43].”
Patients’ perspective on allergen immunotherapy for respiratory allergy
Catamerò, F., Barbaglia, S., Heffler, E. M., Giovannini, M., & Paoletti, G. (2025) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000001110 · Cited by 4
“AIT also modulates innate lymphoid cells 2 ( ILC2s), reducing their pro-inflammatory profile and promoting IL-10-expressing regulatory ILC2 subsets [54,55].”
Role of Group 2 innate lymphoid cells in intranasal sensitization-induced allergic rhinitis in mice
Kato, Y., Takabayashi, T., Shimizu, A., Maegawa, A., Kato, E., Adachi, N., Koyama, K., Saito, K., Yoshida, K., Kidoguchi, M., et al. (2025) · International Immunology · doi:10.1093/intimm/dxaf060 · Cited by 4
Allergen Immunotherapy in Pediatric Respiratory Allergy
Doroudchi, A., Imam, K. H., & Lloret, M. I. G. (2021) · Current Treatment Options in Allergy · doi:10.1007/s40521-021-00280-4 · Cited by 4
Ueda, S., Ito, J., Harada, N., Harada, S., Sasano, H., Sandhu, Y., Tanabe, Y., Abe, S., Shiota, S., Kodama, Y., et al. (2022) · Biomolecules · doi:10.3390/biom12040518 · Cited by 4
“No reaction to ILC2s was observed during the offseason [33].”
BackgroundBiomarkers in oral immunotherapy
Zhu, H., Tang, K., Chen, G., & Liu, Z. (2022) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2200047 · Cited by 4
“…to a significant reduction of 719 | J Zhejiang Univ-Sci B (Biomed & Biotechnol) 2022 23(9):705-731 ILC2s in the peripheral blood of subjects (Lao-Araya et al., 2014; Fan et al., 2016; Mitthamsiri et al., 2018), suggesting that ILC2 detection may be an effective indicator for SCIT monitoring.”
BackgroundZeng, Y., Zeng, Q., Wen, Y., Li, J., Xiao, H., Yang, C., Luo, R., & Liu, W. (2024) · Journal of Allergy and Clinical Immunology Global · doi:10.1016/j.jacig.2024.100212 · Cited by 4
“16 The frequency of peripheral blood ILC2s increased after cat allergen challenge.”
BackgroundMethodBiomarker-driven drug development for allergic diseases and asthma: An FDA public workshop
Rabin, R. L., Altman, M. C., Arshad, S. H., Beger, R. D., Frischmeyer‐Guerrerio, P. A., Goleva, E., Hamilton, R. G., Hershey, G. K. K., Shamji, M. H., Sampson, H. A., et al. (2025) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2025.03.014 · Cited by 4
Self-citationAlternatives to Subcutaneous Immunotherapy for Allergic Rhinitis
Terada, T., & Kawata, R. (2022) · Allergies · doi:10.3390/allergies2010003 · Cited by 4
“Antigen-specific immunotherapy has also been shown to induce IL-10-producing regulatory B cells [66].”
BackgroundKnowledge mapping of interleukin-33: a bibliometric study.
Sun, J., Xia, Y., Zhang, D., Yu, Z., Ning, Y., & Tan, Z. (2023) · PubMed Central · Cited by 4
Effects of subcutaneous allergen immunotherapy on non-targeted allergen-induced immune responses
Nakagome, K., Soma, T., Uchida, T., Sekiya, R., Kobayashi, T., Katayama, K., Iemura, H., Naito, E., Hoshino, Y., Miyauchi, S., et al. (2023) · Allergology International · doi:10.1016/j.alit.2023.07.001 · Cited by 4
Steveling, E. H., Lao‐Araya, M., Koulias, C., Scadding, G. W., Eifan, A. O., James, L. K., Dumitru, A., Penagos, M., Calderón, M. A., Andersen, P. S., et al. (2015) · Clinical and Translational Allergy · doi:10.1186/s13601-015-0087-2 · Cited by 4
“In participants who received SIT levels were comparable to non-atopic controls and correlated with reported seasonal symptom severity [26].”
Self-citationTratamiento de la rinitis alérgica en pediatría en Argentina. Documento de actualización
Vázquez, D., Onetti, C. I., Parisi, C. A. S., Martinez, J. C., Croce, J. S., Moreno, P., García, M., Ivancevich, J. C., & Gómez, R. M. (2020) · Revista Alergia México · doi:10.29262/ram.v67i0.649 · Cited by 4
Biologic drugs and allergen immunotherapy: potential allies
Carlucci, P., Spataro, F., Daddato, M. F., Paoletti, G., & Bona, D. D. (2023) · doi:10.37349/eaa.2023.00014 · Cited by 3
Sublingual Immunotherapy Decreased the Serum Levels of Interleukin‐36γ in Allergic Rhinitis
Qin, X., Wang, C., Li, J., Zhang, X., & Zhang, T. (2024) · Mediators of Inflammation · doi:10.1155/2024/9692031 · Cited by 3
The soothing effect of phlorotannins on cedar pollinosis in Cry j 1-stimulated mice
Sugiura, Y., Usui, M., & Miyata, M. (2023) · Bioscience Biotechnology and Biochemistry · doi:10.1093/bbb/zbad032 · Cited by 3
Bibliometric analysis of T cells in allergic rhinitis
Liu, S., Hu, X., Zhang, J., Lv, L., He, Y., Jiang, L., & Qin, G. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e32756 · Cited by 2
“Concurrently, AR patients affected by pollen exhibited increased ILC2 in peripheral blood during pollen season and a significant decrease after subcutaneous immunotherapy [67], suggesting the involvement of ILC2 in the onset and progression of AR.”
BackgroundPhenotype-oriented immunotherapy of bronchial asthma
Sidorenko, E., & Vykhristsenko, L. (2018) · Immunopathology Allergology Infectology · doi:10.14427/jipai.2018.3.60 · Cited by 2
Immunothérapie allergénique chez l’enfant et l’adolescent
Amat, F., & Labbé, A. (2020) · Revue française d'allergologie · doi:10.1016/j.reval.2020.07.003 · Cited by 2
Allergen-Specific Immunotherapy
Caffarelli, C., Barberi, S., & Traina, G. (2024) · Springer eBooks · doi:10.1007/978-3-031-71283-8_26 · Cited by 1
Tumor necrosis factor receptor 2 in allergen tolerance: a perspective view
Montamat, G., Bazon, M. L., Demczuk, A., Leonard, C., & Ollert, M. W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1613719 · Cited by 1
The role of immunoglobulin E in upper respiratory allergies: mechanisms and therapeutic strategies
Li, S.-D., Li, J., Zhang, Y., & Zhang, L. (2025) · Immunological Medicine · doi:10.1080/25785826.2025.2587474 · Cited by 1
Recent advances in allergen immunotherapy
Fu, W., Zheng, Y., Chen, H., Dong, X. D., Li, W., Liang, H., Chen, S. H., Akdiş, C. A., & Gao, Y. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004189 · Cited by 1
“[33] IL-10-pro-ducing ILC2s (IL-10 + ILC2s) have been identified in AR patients receiving grass pollen SLIT with functions of attenuating Th2 responses and maintaining epithelial barrier integrity.”
Immunotherapy – the causes of sub-optimal efficacy in inhaled allergies
Nittner‐Marszalska, M. (2021) · Alergologia Polska - Polish Journal of Allergology · doi:10.5114/pja.2021.104618 · Cited by 1
“Obserwuje się jednak istotną redukcję ilości ILC2 u pacjentów poddanych AIT w stosunku do osób nieotrzymujących immunoterapii oraz zahamowanie obwodowych ILC2 podczas sezonowej ekspozycji na alergen u osób poddanych AIT [11, 12].”
BackgroundUpdate on Biomarkers to Predict Responders to Allergen Immunotherapy
Moingeon, P. E. (2017) · Current Treatment Options in Allergy · doi:10.1007/s40521-017-0113-9 · Cited by 1
Diverse Mechanisms of Allergen Specific Immunotherapy
Cevhertas, L., & Akdis, M. (2019) · RUDN Journal of Medicine · doi:10.22363/2313-0245-2019-23-3-233-249 · Cited by 1
A review of the mechanisms and biomarkers of allergen immunotherapy
Wilk, M., Ptak, J., Tomczyk, B., Kruczkowska, A., Kanturski, A., & Gomułka, K. (2021) · Medical Studies · doi:10.5114/ms.2021.112388 · Cited by 1
Akdis, M., & van de Veen, W. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-374279-7.16013-8 · Cited by 1
Scadding, G. W. (2015) · Spiral (Imperial College London) · doi:10.25560/33795
Self-citationMechanisms induced by allergen immunotherapy: state of knowledge in 2018
Jutel, M., & Gajdanowicz, P. (2018) · Alergologia Polska - Polish Journal of Allergology · doi:10.5114/pja.2018.80735
“Po AIT u pacjentów uczulonych na pyłki traw zaobserwowano zahamowanie wzrostu liczebności komórek ILC2 (o charakterystyce zbliżonej do komórek Th2) [15].”
BackgroundPractical Considerations in Management of Allergic Asthma
Hanania, N. A., Stern, J. L., & Looney, R. J. (2019) · Respiratory medicine · doi:10.1007/978-3-030-20812-7_9
Huoman, J. (2020) · Linköping University medical dissertations · doi:10.3384/diss.diva-170575
櫻井, 大. (2021) · Nippon Jibiinkoka Tokeibugeka Gakkai Kaiho(Tokyo) · doi:10.3950/jibiinkotokeibu.124.10_1341
戸嶋, 一. (2022) · Nihon Bika Gakkai Kaishi (Japanese Journal of Rhinology) · doi:10.7248/jjrhi.61.237
Yadav, S., Singh, S., Mandal, P., & Tripathi, A. (2022) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2022.5151
神前, 英. (2022) · Nippon Jibiinkoka Tokeibugeka Gakkai Kaiho(Tokyo) · doi:10.3950/jibiinkotokeibu.125.5_853
Hesse, L., Elberink, J. N. G. O., van Oosterhout, A. J. M., & Nawijn, M. C. (2022) · Kompass Neumología · doi:10.1159/000525293
Immunotherapy approaches for managing allergic conditions in children – A narrative review
Agrawal, A., & Agrawal, R. C. (2024) · Indian Journal of Child Health · doi:10.32677/ijch.v11i2.4597
Present and future possibilities of immunotherapy
Fábos, B. (2024) · Bőrgyógyászati és Venerológiai Szemle · doi:10.7188/bvsz.2024.100.2.3
Therapy of Allergic Rhinitis Using Ribavirin Spray to Clear Nasal Commensal VirusesPreprint
Dong, Y., Wang, T., Fan, Y., Zhou, Y., Li, Z., Qin, Y., Wang, Z., Liu, Y., Liu, S., Liang, C., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.5005077
Pavón-Romero, G. F., Jiménez, F. R., Palos, D. C., & Teran, L. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-128-24465-4.00074-0
Kolesnykova, O. (2025) · Immunology and Allergy Science and Practice · doi:10.37321/immunology.2025.1-07
Modulation of type 2 inflammation during grass pollen-specific sublingual immunotherapy
Salvati, L., Capone, M., Mazzoni, A., Vanni, A., Lamacchia, G., Scaletti, C., Parronchi, P., Liotta, F., Annunziato, F., Cosmi, L., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1784244
Animal Models of Allergen Immunotherapy for Allergic Airway Inflammation
Zhang, F., Sun, S., Wu, X., Ma, J., Yu, D., Liu, Z., & Yao, Y. (2026) · Allergy · doi:10.1111/all.70323
“Additionally, SCIT with birch or grass pollen reduces group 2 innate lymphoid cells (ILC2) frequency in the peripheral blood of patients with allergy [58, 59].”
Caractérisation transcriptomique des cellules lymphoïdes innées
Crinier, A. (2020) · theses.fr (ABES) · doi:10.70675/850e38aazc227z4187z9c41z07c47cac00d9
Mécanismes de l'immunothérapie épicutanée des allergies alimentaires
Laoubi, L. (2020) · theses.fr (ABES) · doi:10.70675/848d7714za7e9z43d9zacaez47cd7d35182d
Etude des mécanismes de régulation de l'activation des cellules natural killer
Guia, S. (2021) · theses.fr (ABES) · doi:10.70675/fe8a748dzb006z40a0z8e07z1043717cbdd0
戸嶋, 一., 村尾, 拓., 川北, 憲., 中村, 圭., 新井, 宏., 松本, 晃., 清水, 志., 神前, 英., 清水, 猛., Tojima, I., et al. (n.d.) · Institutional Repositories DataBase (IRDB)
Melnikova, D. N., Potapov, A. E., Zavoiko, D., & Ovchinnikova, T. V. (2026) · Membranes · doi:10.3390/membranes16080277
“AIT has been demonstrated to induce a shift in ILC2 toward protective IL-10 + KLRG1 + phenotype and to inhibit proallergic seasonal increase in IL-13 + ILC2s [66,67].”
LÜCKMANN, L. F., Dal-Pizzol, H. R., Lückmann, L. M., Salini, D., Hasckel, B. C., Minati, M., Kluwe‐Schiavon, B., & Tatiana, B. (2026) · Immunology · doi:10.1111/imm.70202
Metadata
- Authors
- Lao-Araya, M., Steveling, E., Scadding, G. W., Durham, S. R., & Shamji, M. H.
- Affiliations
- Asthma UK (GB)
- Corresponding author
- Shamji, Mohamed H.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2014-11
- Volume
- 134
- Issue
- 5
- Pages
- 1193-1195.e4
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2030393991
- Cited by
- 200
- References
- 9
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 14 · 2023: 17 · 2022: 17 · 2021: 29 · 2020: 21 · 2019: 18 · 2018: 22 · 2017: 24 · 2016: 14 · 2015: 9 · 2014: 1
- FWCI
- 12.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Allergy and Clinical Immunology (publishedVersion)
- PubMed (publishedVersion)
- edoc (University of Basel) (submittedVersion)
- Funders
- Wellcome Trust (097881/Z/11/Z)
- Immune Tolerance Network (N01 AI15416)
- Asthma and Lung UK
- Imperial College London
- Chiang Mai University
- National Institutes of Health (n01ai15416-28-0-11, N01-AI-15416)
- Medical Research Council
- Faculty of Medicine, Chiang Mai University
- National Institute of Allergy and Infectious Diseases (N01 AI 15416)
- Topics
- Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
- Life Sciences › Immunology and Microbiology › Immunology › IL-33, ST2, and ILC Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- innate lymphoid cells type 2, subcutaneous immunotherapy, grass pollen allergy, allergic rhinitis, seasonal variation, Th2 immune response, IL-4, IL-5, IL-13, nasal mucosa inflammation
- MeSH terms
- Allergens, Desensitization, Immunologic, Female, Rhinitis, Allergic, Seasonal, Humans, Lymphocytes, Male, Pollen, Seasons, Cytokines, Phleum
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
